Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma

Jeong Hun Kim, Jin Hyoung Kim, Young Suk Yu, Dong Hun Kim, Bon Hong Min, Kyu Won Kim

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.

Original languageEnglish
Pages (from-to)1373-1377
Number of pages5
JournalOncology Reports
Volume18
Issue number6
Publication statusPublished - 2007 Dec 1

Fingerprint

Retinoblastoma
Arginine
Argininosuccinate Synthase
Neoplasms
arginine deiminase
Cell Death
Therapeutics
Cell Proliferation
Drug Therapy

Keywords

  • Arginine deiminase
  • Arginine deprivation
  • Argininosuccinate synthetase
  • Retinoblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kim, J. H., Kim, J. H., Yu, Y. S., Kim, D. H., Min, B. H., & Kim, K. W. (2007). Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncology Reports, 18(6), 1373-1377.

Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. / Kim, Jeong Hun; Kim, Jin Hyoung; Yu, Young Suk; Kim, Dong Hun; Min, Bon Hong; Kim, Kyu Won.

In: Oncology Reports, Vol. 18, No. 6, 01.12.2007, p. 1373-1377.

Research output: Contribution to journalArticle

Kim, JH, Kim, JH, Yu, YS, Kim, DH, Min, BH & Kim, KW 2007, 'Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma', Oncology Reports, vol. 18, no. 6, pp. 1373-1377.
Kim, Jeong Hun ; Kim, Jin Hyoung ; Yu, Young Suk ; Kim, Dong Hun ; Min, Bon Hong ; Kim, Kyu Won. / Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. In: Oncology Reports. 2007 ; Vol. 18, No. 6. pp. 1373-1377.
@article{cc7aea8aa296447bac56756ae1779b5d,
title = "Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma",
abstract = "In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.",
keywords = "Arginine deiminase, Arginine deprivation, Argininosuccinate synthetase, Retinoblastoma",
author = "Kim, {Jeong Hun} and Kim, {Jin Hyoung} and Yu, {Young Suk} and Kim, {Dong Hun} and Min, {Bon Hong} and Kim, {Kyu Won}",
year = "2007",
month = "12",
day = "1",
language = "English",
volume = "18",
pages = "1373--1377",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma

AU - Kim, Jeong Hun

AU - Kim, Jin Hyoung

AU - Yu, Young Suk

AU - Kim, Dong Hun

AU - Min, Bon Hong

AU - Kim, Kyu Won

PY - 2007/12/1

Y1 - 2007/12/1

N2 - In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.

AB - In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.

KW - Arginine deiminase

KW - Arginine deprivation

KW - Argininosuccinate synthetase

KW - Retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=38449091831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449091831&partnerID=8YFLogxK

M3 - Article

C2 - 17982619

AN - SCOPUS:38449091831

VL - 18

SP - 1373

EP - 1377

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -